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Abstract. The current International Council for Harmonisation of Technical Requirements
for Pharmaceuticals for Human Use (ICH) methods for determining the supported shelf life of a
drug product, described in ICH guidance documents Q1A and Q1E, are evaluated in this paper.
To support this evaluation, an industry data set is used which is comprised of 26 individual
stability batches of a common drug product where most batches are measured over a 24 month
storage period. Using randomly sampled sets of 3 or 6 batches from the industry data set, the
current ICH methods are assessed from three perspectives. First, the distributional properties of
the supported shelf lives are summarized and compared to the distributional properties of the
true shelf lives associated with the industry data set, assuming the industry data set represents a
finite population of drug product batches for discussion purposes. Second, the results of the ICH
Bpoolability^ tests for model selection are summarized and the separate shelf life distributions
from the possible alternative models are compared. Finally, the ICH methods are evaluated in
terms of their ability to manage risk. Shelf life estimates that are too long result in an
unacceptable percentage of nonconforming batches at expiry while those that are too short put
the manufacturer at risk of possibly having to prematurely discard safe and efficacious drug
product. Based on the analysis of the industry data set, the ICH-recommended approach did not
produce supported shelf lives that effectively managed risk. Alternative approaches are required.
KEY WORDS: stability; shelf life estimation; FDA; ICH Q1A/Q1E; managing risk.
INTRODUCTION
Overview
In 2006, the Product Quality Research Institute (PQRI)
established a Stability Shelf Life Working Group (referred to as
the BWorking Group^ in this article) with the mandate to
investigate current statistical methods for estimating shelf life
based on stability data. The Working Group is composed of
pharmaceutical, regulatory, and statistical scientists from industry,
government, and academia.As one of its first actions, theWorking
Group reviewed available literature and applicable guidance
documents, and discussed current industry and regulatory prac-
tices related to determining the shelf life for pharmaceutical
products.Different issueswith the current practiceswere discussed
along with possible statistical approaches to resolve them. The
Working Group engaged in discussions to review and summarize
available descriptions of shelf life, evaluating their benefits,
drawbacks, and consequences to better target the appropriate
research questions for statistical discussions. Key results from
these discussions are published in theWorking Group’s first paper
(1). The concepts and terminology set forth in that paper are used
throughout this review. In particular, the product shelf life is the
true but unknown limit on the period of storage time during which
the pharmaceutical or drug product remains within specifications
and is therefore considered effective and fit for use. Any suitably
conservative estimate of the product shelf life, as supported by
statistical methods, is called the supported shelf life.
This second paper is a report on the continuation of
those discussions which again are meant to raise public
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awareness of the existing different interpretations of shelf life
and to stimulate a broader public discussion on these topics,
which are relevant for drug products, drug substances, clinical
supplies, etc. In this process, the Working Group has
considered existing guidelines but sometimes taken the
liberty to question elements of these for the purpose of
potentially developing an alternative methodology.
The International Council for Harmonisation of Tech-
nical Requirements for Pharmaceuticals for Human Use
(ICH) brings together regulatory authorities and the
pharmaceutical industry to discuss scientific and technical
aspects of drug registration. For stability testing, ICH Q1A
(2) specifies that the supported shelf life for a drug product
be set as the storage time during which drug batches are
expected to remain within specification. Similarly, ICH Q1E
(3) notes that the strategy for estimating the supported shelf
life of a drug product is to determine the storage time during
which the critical attributes of the drug product remain
acceptable for all future batches, manufactured, packaged,
and stored under similar conditions. Both guidance docu-
ments highlight the batch as the focal point of interest. The
current statistical methods for determining a supported shelf
life outlined in ICH Q1A and Q1E assume that a simple
linear regression model is adequate to describe the observed
data obtained from a stability study. In addition, the ICH
guidance documents allow other statistical models to be
used, e.g., a quadratic polynomial or nonlinear model, when
appropriate.
The ICH statistical methods for estimating the shelf life
have long been the subject of discussions, publications, and
conference presentations, in which the Working Group has
participated. However, to the Working Group’s knowledge,
Kiermeier et al. (4) and Quinlan et al., (5) using simulated
data, provide the first review of the results of these ICH
methods. The current paper continues the review of these
methods through the analysis of a real-life industry data set
provided to the Working Group by a PQRI-member phar-
maceutical company. This industry data set is used for all
discussions, examples, and computations and is comprised of
26 individual stability batches with most batches having
24 months of stability data. Each batch represents the results
of a stability-limiting product characteristic; here, percent
assay or potency measured over storage time. As in the ICH
guidance documents, a simple linear regression model is
assumed and is appropriate for the industry data set. While
our focus is on the ICH methods for estimating shelf life, the
statistical summaries and figures described herein, as well as
the emphasis on risk, provide a novel framework for
determining if a particular method produces a Bgood^
estimate of the true product shelf life. This will be further
explored in a future paper.
The primary purpose of this paper is to evaluate the ICH
methods for determining the supported shelf life in terms of
their distributional properties and in terms of the proportion
of batches conforming to specifications at the supported shelf
life. To do so, an evaluation of the ICH stability shelf life
estimation methods is considered from three perspectives to
highlight different aspects of the estimation methods. First,
the industry data set is used assuming the 26 individual
stability batches represent a common pharmaceutical product
from a production process under control. Here, for the
purpose of discussing and evaluating the ICH methods, the
26 stability batches of the industry data set are treated as if
they represent the entire population of stability batches for
the pharmaceutical product. Second, a model selection
procedure is outlined in the ICH guidance documents,
commonly referred to as the Bpoolability^ tests, and is a
major component to the ICH methods for estimating shelf
life. To evaluate the poolability testing process in terms of the
ICH methods, comparisons are made among the supported
shelf life distributions for each of the variations of the simple
linear regression model. Third, as stated in both ICH Q1A
and Q1E, a supported shelf life of a drug product must define
the storage time during which drug product batches are
expected to remain within specifications. This storage time is
applicable to all future batches that are manufactured,
packaged, and stored under similar conditions. While not
mentioned as such in these guidance documents, this defines a
type of quality statement. Using the industry data set, the
capability of a typically sized stability study (usually three
batches but sometimes more) to generate a supported shelf
life that conforms to this quality statement is investigated with
respect to both patient risk and business risk.
A Brief Review of the ICH Methods
The current ICH methodology for determining the
supported shelf life from a stability study assumes a fixed
batch analysis. In a fixed batch analysis, the variation among
batches is interpreted as differences in batch characteristics or
differences in the fixed intercept and slope parameters which
uniquely characterizes each batch’s response over storage
time, measured traditionally in months. Typically, three
batches (occasionally more) of drug product are represented
in a stability study for a New Drug Application (NDA) or
Marketing Authorization Application (MAA) filing and are
referred to as the registration batches.
The ICH shelf life analysis strategy begins with assuming
that a simple linear regression model is adequate to characterize
the response data from each of the batches, allowing for
differences in the estimates of the intercept and slope parame-
ters among the batches. Next, a series of poolability tests are
conducted using a regression model selection procedure to
determine how best to statistically characterize the batches. The
poolability tests consider three variations of a simple linear
model to determine the best fitted regression model to
characterize trend across storage time in the set of stability
batches: (1) allowing separate intercepts and separate slopes for
the regressions fitted to each stability batch; (2) allowing
separate intercepts with a common slope; and (3) a single
regression fitted with a common intercept and common slope to
the set of stability batches. In practice, for some stability-limiting
responses, a fourth model is included that allows for (4) a
common interceptwith different batch slopes.Depending on the
selected statistical model, a 95% confidence interval about the
overall batch mean response or the worst case individual batch
mean response is derived and the supported shelf life is defined
as that storage time in which the confidence interval first
intersects the acceptance criterion. In the next section, an
industry data set is presented in which the response decreases
over time. The remainder of this paper will utilize this data set.
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MATERIALS AND METHODS
An Industry Data Set
To facilitate and to make the discussion as relevant as
possible to the determination of the supported shelf life of a
drug product, an industry data set is used for all computations
and examples. These data were offered to the Working
Group for their use from an anonymous PQRI member
company. The data were blinded from the Working Group in
terms of drug product and measurement units on the
response. The industry data set represents 26 individual
batches of a common pharmaceutical or drug product, where
most batches remained on stability for a 24-month period and
came from a manufacturing process assumed to be under
statistical control. The response measure is percent assay
(potency). For this discussion, it is assumed that (1) a simple
linear regression model is appropriate to describe the stability
data from each of the 26 batches, (2) the stability data
themselves represent true batch mean responses, and (3) the
determination of the overall regression line provides the true
response trend among the 26 batches. That is, the regression
line obtained for a particular batch represents the true
regression line for that batch. This in turn allows determina-
tion of the true batch shelf life for each stability batch in the
assumed finite population of 26 batches. The distribution of
the true batch shelf lives corresponding to the 26 stability
batches of the industry data set is used as a reference for
evaluating the ICH approach for determining a supported
shelf life. Consistent with the traditional ICH stability shelf
life study scenario, sets of three or more stability batches are
randomly sampled without replacement from the industry
data set such that each set is sampled only once. Each set of
randomly selected batches is used to estimate the regression
parameters and determine a corresponding supported shelf
life following ICH methods. The distribution of the supported
shelf lives from the random sampling of the industry data set
is then compared to the reference distribution of true batch
shelf lives corresponding to the industry data set treated as a
population.
The batch response data for the industry data set are
shown in Fig. 1. The vertical axis is the percent assay or
potency response which represents a stability-limiting re-
sponse variable for the drug product. Acceptance criteria are
set at 90 and 110%, as is typical for a potency specification in
the USA. The horizontal axis is stability storage time in
months, which is terminated at 48 months for ease of
presentation. The actual range of storage times at which the
batch lines intersect the lower acceptance limit ranges from
18 months (as shown) to 169.5 months.
The 26 estimated batch regression lines derived from the
industry data set (solid black lines in Fig. 1) are assumed to
represent the true regression lines for each batch. Also, the 26
estimated batch mean responses derived from the regression
analysis at a particular time point are assumed to represent
the 26 true batch mean assay responses at that time point. If
the batch response data are first averaged and a regression
analysis is performed on these averages, the resulting
estimated line (the dashed line in Fig. 1) is assumed to
represent the true regression trend among the overall batch
mean responses. This overall true or population mean line
intersects the lower acceptance criterion at 37.8 months
(vertical reference line in Fig. 1), which, for our purposes,
will define the true product shelf life.1 In practice, of course,
only a sample of batches is included in the stability study and
variation is present both within and among batches. The
variation depicted in Fig. 1 among the data and the intercepts
and slopes of the 26 batch regression lines is typical of what
can be observed in stability study results. This variation along
with a consideration of risk leads to supported shelf lives that
can be much shorter than the true product shelf life of a drug
product. This is described in detail in the Results and
Discussion Section.
Product, Batch Mean, and Shelf Life Distributions
There are three distributions that are important to the
discussion of shelf life: The product distribution, the batch
mean distribution, and the shelf life distribution. Any method
used to estimate the product shelf life has to account for both
the risk associated with patients using a potentially subpotent
product (patient risk) and the risk associated with a manu-
facturer having to set a short shelf life, which could lead to
discarding good product (business or industry risk). These
distributions provide the necessary framework to characterize
the properties of a good estimation procedure. The product
distribution and batch mean distribution are both defined
with respect to the stability-limiting response variable,
depicted as the vertical axis in Fig. 1. The shelf life
distribution is defined with respect to the storage time,
depicted as the horizontal axis in Fig. 1.
While it is recognized that stability testing is often
performed on composite samples (multiple dosage units
ground or dissolved together) such that unit dose uniformity
is averaged out to some extent, the assumption is made here
that each measured percent assay result in the industry data
set represents the true percent assay associated with a single
dosage unit. Under this assumption, the product distribution
describes the range of product percent assay or potency
available for patient usage at any given storage time
1 The true product shelf life is an elusive concept to
discuss and equally elusive to represent precisely with any
mathematical rigor. Historically, for practical purposes, the
true product shelf life has been defined as the storage time
at which the mean of the product distribution, following
some response trend across storage time, intersects the
acceptance criteria. This is the basis for referring to
37.8 months as the true product shelf life of the industry
data set. In practice, when there is between batch and
within-batch variation, if the mean of the product distribu-
tion is used to define the true product shelf life, half of the
product distribution will fall out of specification at expiry,
which appears to be in conflict with the ICH philosophy.
This paper is a step towards developing a coherent
framework to discuss the true product shelf life. While some
author’s (e.g., Kiermeier, et al. (6)) have proposed defining
the true product shelf life to ensure that a predefined
proportion of dosage units meet the acceptance criterion at
expiry, until an agreed upon framework is developed, it is
necessary to continue to apply the historic interpretation of
true product shelf life discussed previously.
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(conceptually) although usually just expiry is of interest. It
includes both between-batch and within-batch variation and
is represented by the dots in Fig. 1. It is the product
distribution that directly confronts the patient taking the drug
product.
The batch mean distribution describes the variation
among the batch mean responses derived from the regression
analysis at any given storage time although, like the product
distribution, usually just expiry is of interest. It is the batch
mean distribution that is of primary interest to regulatory
agencies when setting stability shelf life limits and to the
pharmaceutical industry when determining the stability
profile and overall acceptability of the drug product. The
batch mean distribution shown in Fig. 2 is defined at a storage
time of 37.8 months. The horizontal axis represents product
potency expressed as percent assay where the midpoint of
each bracket is labeled. The vertical axis is the frequency or
number of batches with mean potency response in each
bracket. Thirteen (50%) of the stability batches have
estimated means below (outside) the lower acceptance
criterion of 90% of product strength at this storage time and
are thus considered nonconforming.
The shelf life distribution is defined across the horizontal
axis representing the storage time corresponding to where each
batch mean response intersects the lower acceptance criterion
(in this case). Typically, the shelf life distribution is a positively
skewed distribution unlike the product distribution and batch
mean distribution, which are generally assumed to be normally
distributed. The shelf life distribution for the industry data set is
summarized in Fig. 3. The horizontal axis represents storage
time in months where the midpoint of each bracket is labeled.
The vertical axis describes the frequency or number of batches
with the indicated shelf life in each bracket.
There is an interesting relationship between the batch
mean distribution and the shelf life distribution. For a given
storage time, T, the fraction of batches with shelf lives less
than or equal to T is the same as the fraction of batches with
batch means less than or equal to the lower acceptance
criterion. For example, in Fig. 3, the 5th quantile of the shelf
life distribution is 25.1 months. From Fig. 1, at 25.1 months,
only 2 out of the 26 batch means (7.7%) fall at or below the
90% specification limit. Similarly, the 75th quantile of the
shelf life distribution is 47.6 months where 20/26 (76.9%) of
the batch means fall below the 90% specification limit.
Unlike the industry data set, where the true batch means
and true shelf lives are assumed known, in practice, these
quantities are unknown and need to be estimated from the
available stability data. Because the intent is to obtain conser-
vative estimates, the relationship described earlier no longer
holds. In general, quantiles of the individual distributions do not
correspond to each other unless there is no variation among the
batch slopes (Quinlan et al. (5)). Themedians (50th quantiles) of
the two distributions do correspond to each other. A schematic
of this relationship is depicted in Fig. 4, where the vertical axis
represents the values of a stability-limiting response variable
and the horizontal axis is storage time. The solid line is the
population overall mean batch response trend for a stability-
limiting response variable which is increasing over storage time.
The dashed line represents a plausible relationship between the
distributions which depends on the shape and variances of the
respective distributions. Note that by using the overall mean
batch response, the batch mean distribution centers on the
acceptance limit where half the distribution is out of
specification.
RESULTS AND DISCUSSION
Applying ICH Methods for Estimating the Product Shelf Life
to the Industry Data Set
Overall Summary
To evaluate the ICH methods for estimating the product
shelf life, the industry data set is used to sample sets of three
and six batches to reflect the typical range in sample size
(number of batches) of most stability studies. Following ICH
Fig. 1. True batch mean responses and corresponding regression lines for 26 batches of a
common pharmaceutical product measuring percent assay versus storage months
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guidance, the sampled sets of batches are used to estimate the
product shelf life. A simple linear regression model is used to
characterize batch assay response over storage time. The
poolability testing strategy is then conducted, allowing for all
four possible regression models as described previously.
Based on the resulting regression model from the poolability
tests, the estimated (i.e., supported) shelf life is obtained
based on when the appropriate 95% confidence interval
crosses the lower acceptance criterion. While similar results
are expected for the two cases (three batches vs six batches),
for the sake of completeness, the full details of both are
presented with important differences noted when they occur.
There are 2600 unique combinations of sets of three
batches from the 26-batch industry data set. Each combina-
tion set of three batches represents a stability study.
Following ICH methods, a supported shelf life is determined
through a fixed batch analysis for each of these 2600
combination sets. Figure 5 is the summary distribution of
the 2600 supported shelf lives truncated to 48 storage months
for ease of presentation. The spike in frequency for supported
shelf lives between 15 and 17 months is a result of including
one or more rapidly degrading batches in the sample (see also
Fig. 1). In these cases, the three sampled batches are usually
not allowed to be pooled in the sense that a common slope
Fig. 2. The batch mean distribution for the industry data set as defined by the batch mean
responses at 37.8 months of storage derived from the individual (true) regression lines.
Thirteen (50%) of the batches have batch mean responses below 90%
Fig. 3. The shelf life distribution defined by the storage time corresponding to when the
true regression line for each stability batch in the industry data set intersects the acceptance
criterion
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and/or common intercept estimate among the batches is not
achievable. When this occurs, the data and information in the
other two batches are only used in obtaining an estimate of
the common variance, and not directly used in deriving the
supported shelf life. In this case, a 95% confidence band
about the worst case batch regression line leads to a short
supported shelf life.
Correspondingly, if batches demonstrating slower degra-
dation than typical are included in the sample, this can also
prevent the pooling of the slopes and/or intercepts. In this
case, though, even if pooling cannot be achieved, the effect on
the supported shelf life is not as dramatic because the worst
case batch still demonstrates a typical rate of degradation.
However, if the data supports a common intercept and slope,
the supported shelf life is then based on the overall mean
response and can therefore be much longer. This is why the
shelf life distribution tends to be positively skewed. Note that
neither excessively short nor excessively long supported shelf
life estimates are desirable.
Figure 6 is a similar summary of the supported shelf lives
from combination sets of six batches. There are 230,230 unique
combinations when selecting sets of six batches from the 26-
batch industry data set. Analyzing all the possible combinations
of six batches is not manageable. A randomly selected
representative sample of 20,000 combination sets of six batches
is used to produce Fig. 6 and for the following discussions.
Similar to Fig. 5, the erratic spikes in the lower section of
the shelf life distribution shown in Fig. 6 are due to the increase
in the number of batches from three to six which then increases
the probability of sampling one ormore of the rapidly degrading
stability batches. This in turn increases the probability of not
being able to pool the batches which then results in a shorter
supported shelf life. The mean supported shelf life for sets of
three batches is 26.0 months (Fig. 5), whereas the mean
supported shelf life for sets of six batches is 23.4 months (Fig.
6). Similarly, a decrease in corresponding quantiles can be seen
comparing Figs. 5 and 6 indicating a negative shift in the
supported shelf life distribution with increase in the number of
batches. This relationship is also depicted in Fig. 7 which
displays the cumulative distributions of the ICH-supported shelf
lives for both three and six batches. The cumulative distribution
of the true batch shelf lives is also shown in Fig. 7 for comparison
purposes. Note that the cumulative distribution corresponding
to six batches is almost entirely to the left of the cumulative
distribution corresponding to when only three batches are
included in the stability study. With the current ICH methodol-
ogy, increasing the number of batches in a stability study does
not necessarily result in a longer supported shelf life.
In Fig. 7, the cumulative distribution of the true batch shelf
lives is to the right of the corresponding cumulative distributions
of the supported shelf lives as derived based on the ICH
methods. This is expected since any reasonable estimation
procedure will necessarily have to produce estimates of the
product shelf life at which future batches are expected to remain
within specification (ICH Q1A).
Fig. 4. Schematic of the relationship between the batch mean
distribution and the shelf life distribution. The median of the shelf
life distribution (red vertical dashed line) defines a storage time at
which 50% of the batches are nonconforming
Fig. 5. The supported shelf life distribution based on ICH guidance methods using three
batches
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Model-Specific Results
The ICH guidance specifies that a poolability assessment
should be conducted to determine the best fitted simple linear
regression model to characterize the trend demonstrated by
the batches. The poolability procedure allows for modeling
the batches using either a common regression line for all
batches or for separate intercept and/or slope parameters for
each batch. The previous section focused on the distribution
of the supported shelf life using the ICH methodology
without regard of the results from a poolability assessment.
Through the poolability assessment, the best fitted simple
linear regression model or system of models characterizing
each individual batch was determined, allowing for all four
possible alternative models. Those four possible alternative
models to best characterize response trend across storage
time for the batches are as follows:
& Model 1: separate intercepts and separate slopes
estimated for each batch,
& Model 2: common intercept and separate slopes
estimated among batches,
& Model 3: separate intercepts and a common
slope estimated among batches,
& Model 4: common intercept and a common slope
estimated for all batches.
Using the industry data set and considering all 2600
possible combination sets of three batches, statistical summa-
ries of the distributions of supported shelf lives corresponding
to each specific model are provided in Fig. 8a–d. The
poolability analysis was conducted as would be for the typical
stability study regression analysis following the ICH analysis
strategy.
There is a dependence of the distributions of the
supported shelf life on the outcome of the poolability testing.
For those models defined by separate slope estimates for each
batch, models 1 and 2 summarized in Fig. 8a, b, respectively,
the mean supported shelf life and related distributional
quantiles for each model are similar. For those models
defined by a common slope estimate for each batch, models 3
and 4 summarized in Fig. 8c, d, respectively, the mean
supported shelf life and related distributional quantiles for
each model are also similar. However, there is an overall shift
to shorter storage times in the supported shelf life distribu-
tions comparing models 1 and 2 (separate slopes) to models 3
and 4 (common slopes).
To elaborate on this, suppose there is a business need to
have a supported shelf life that is no less than 24 months. The
above results imply that if a separate slope model is chosen,
there is only about a 50% chance of attaining the required
shelf life (median storage time ≈ 24 months in Fig. 8a, b). If a
common slope model is chosen, then there is about a 90%
chance of attaining a shelf life of 24 months (10th
quantile ≈ 24 months in Fig. 8c, d). For the industry data
set, while there is almost equal chance of the poolability test
resulting in a separate slope model compared to a common
slope model (48% (466 + 788)/2600) compared to 52%
((983 + 363)/2600), there is a greater industry or business
risk associated with having to use a separate slope model
instead of a common slope model.
Using the industry data set by considering a random
sample of 20,000 of the 230,230 possible combination sets of
six batches, statistical summaries of the distributions of
supported shelf lives categorized by the results of the
poolability tests to determine the best fitted regression model
are summarized in Fig. 9a–d.
With six batches, similar to using three batches, there is a
dependence of the results of the poolability tests for selecting
the best fitted regression model on the distributions of the
supported shelf life for each regression model. However, with
six batches, there is a lesser chance of concluding that a common
slope model is appropriate for characterizing the batches versus
a model where the common slope assumption is not justified, 45
versus 55%, respectively. Using six batches, the mean supported
shelf life and distributional quantiles for models 1 and 2 are
similar, as shown in Fig. 9a, b, respectively. This pattern is not as
evident for models 3 and 4, as shown in Fig. 9c, d, respectively,
with the mean supported shelf life and the distributional
Fig. 6. The supported shelf life distribution based on ICH guidance using six batches
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quantiles of model 3 being generally smaller than those for
model 4. This is because the increase in the number of batches
increases the probability that at least one rapidly degrading
batch is included in the set of six batches preventing the
poolability tests to conclude that a common intercept/slope
model is adequate to characterize the overall response trend
over storage time. Note that when comparing common slope
models, 94.4% (8451/(8451 + 499)) of the combination sets from
the industry data set resulted in model 3 best characterizing
response trend and only 5.6% of the combination sets allowed
for both a common intercept and a common slope.
Again, assume there is a business need to have a
supported shelf life that is no less than 24 months. The above
results imply that if a separate slope model is chosen, there is
only about a 25% chance of attaining the required shelf life
(75th quantile ≈ 24 months in Fig. 9a, b). If a separate
intercept/common slope model is chosen, then there is about
a 90% chance of attaining a shelf life of 24 months (10th
quantile ≈ 24 months in Fig. 9c). For a common intercept/
common slope model, all of the supported shelf lives were at
least 24 months (Fig. 9d). As for the case of three batches, the
choice of model can significantly impact business risk. Of
course, whether or not a shelf life of 24 months (or longer) is
satisfactory from a patient risk perspective would also have to
be factored into the manufacturer’s deliberations regardless
of how many batches are placed on stability.
Evaluating the Risk/Benefit of Estimating a Product Shelf
Life Using the ICH Approach
The primary objective of any shelf life estimate is to
mitigate the patient’s risk through the assurance of a safe and
efficacious drug product throughout the drug product’s storage
life. For a given storage time, usually taken to be the expiration
date of the drug product, patient risk can be defined in terms of
the product distribution, the batch mean distribution, or the
shelf life distribution. In terms of the product distribution,
patient risk is defined as the proportion of the individual dosage
units that fall outside of the acceptance criteria (i.e., out of
specification) at expiry. Because it is often not feasible to
adequately characterize the product distribution at expiry, for
both regulatory and industry reasons, a surrogate definition of
patient risk is used, namely, the proportion of the batch mean
distribution outside the acceptance criteria at expiry, as shown in
Fig. 10. Recall that the batch mean distribution is defined by the
intersection points of the individual batch mean responses,
derived from a regression analysis, at expiry. The shelf life
distribution is defined by the distribution of shelf lives obtained
through the batch mean distribution corresponding to each
batch’s shelf life. Because of the duality between the batchmean
distribution and the shelf life distribution, patient risk can also
be assessed through the latter distribution as the proportion of
batches with shelf lives that are less than the estimated product
shelf life, as shown in Fig. 10. Industry risk is the counterpart to
patient risk and is of concern when the product shelf life is
sufficiently short to force the batch mean distribution to be well
within the acceptance criteria or specification at expiry. Having a
shelf life that is too short may necessitate early discard of still
effective product and not meet the business needs of the
manufacturer. A Bgood^ estimate of shelf life is therefore one
that, in some sense, balances these two competing risks.
To validate any shelf life estimate and quantify the risk to
the patient, how well the product distribution and batch mean
distribution are managed with respect to the acceptance
criteria must be considered. Traditionally, this is done at
expiry as defined by the supported shelf life. The schematic in
Fig. 4 is a depiction of an example where 50% of the
distribution of batch means is out of specification at a storage
time corresponding to when the overall mean response trend
intersects the acceptance criteria. Figure 10 is a depiction of
an example where the supported shelf life is derived to
minimize risk to the patient while ensuring that it still meets
the business needs of the manufacturer. Note that the
supported shelf life delineated at the vertical dashed line in
Fig. 7. Cumulative distribution functions of the supported shelf lives for three and six
batches following ICH guidance and the corresponding true batch shelf lives from the
industry data set
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Fig. 10 is not defined by where the mean response intersects
the acceptance criteria. This will be further explored in a
future paper.
Assessing the ICH Approach Using the Batch Mean
Distribution
To assess how well the ICH methods perform in regard
to managing risk, the industry data set is again used to
represent a finite population of product stability batch data
for discussion and comparison purposes. Using a sampling of
all possible combinations of three (or random sample of all
possible combinations of six) batches, the supported shelf life
is computed for each combination set following ICH guidance
methods. As mentioned previously, because shelf life often
exceeds the duration of the stability study, it is difficult to
correctly define the proportion of the product distribution
that would be out of specification with respect to an
acceptance criteria at expiry. A pragmatic solution is to
characterize each batch by the predicted mean response of
the stability-limiting variable as determined from a regression
analysis thereby defining the batch mean distribution at
expiry. For each combination set of batches, a batch from
the industry data set will be considered nonconforming if the
predicted mean response for that batch is out of specification
at expiry as determined by the supported shelf life. The
proportion of the 26 batches from the industry data set that
are nonconforming is recorded for each combination set of
batches. In addition, the number of occurrences when all of
the 26 batches from the industry data set are within
specification bounds (conforming), as defined by each batch’s
predicted response being within specification bounds, is also
recorded. These results are summarized in Table I catego-
rized by the regression model type best fitted to the three
batches through the poolability tests and for all combinations
of three combination batch sets.
As was concluded in previous discussions, the ability to
fit, or not fit, a regression model with a common slope
estimate for all batches in each combination set of batches
influences the summarized results. Here, all supported shelf
life estimates are based on 95% confidence intervals about
the mean pooled response or about the mean response of the
worst case batch results as determined by the poolability tests.
From Table I, if the mean response trends are characterized
by individually estimated batch slopes, models 1 and 2, the
average proportion of nonconforming batches at expiry is 6.1
and 7.0%, respectively. Recall from Fig. 8a, b that the mean
(range) of the supported shelf lives was 22.9 (14.3–39.5)
Fig. 8. Distribution of supported shelf lives based on three batches corresponding to a model 1: separate intercepts and separate slopes, b
model 2: common intercept and separate slopes, c model 3: separate intercepts and common slope, d model 4: common intercept and common
slope.
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months and 23.3 (13.3–40.4) months, respectively. Fitting a
regression model with a common slope estimated among
batches results in a larger average proportion of
nonconforming batches, 11.9 and 20.6% for models 3 and 4,
respectively. From Fig. 8c, d, the mean (range) of the
supported shelf lives was 27.8 (0.00–43.2) months and 31.2
(20.9–≥ 48) months, respectively. The overall range in the
proportion of nonconforming batches among the 2600
combinations is quite broad at 0.0 to 76.9%.
As also displayed in Table I, the proportions of
combination sets corresponding to batch mean distributions
being completely within acceptance criteria are 33.7% and
17.0% for models 1 and 2, respectively, assuming individual
slope estimates among batches. Among those combination
sets, the corresponding mean (range) of the supported shelf
lives is 15.6 (14.3–16.5) months and 15.1 (13.3–18.1) months,
respectively. For those batch combination sets where a
common slope is fitted, models 3 and 4, the corresponding
proportions are 2.2% and 0.0%, respectively. For the
combination sets fit by model 3, the corresponding mean
(range) of the supported shelf lives is 14.9 (0.0–17.6) months.
Note that all of the combination sets associated with model 4
contained at least one nonconforming batch. From Figs. 1 and
2, it is not surprising that all of the maximum supported shelf
lives listed in the last column in Table I are approximately
18 months or less since the minimum true shelf life is
18.2 months. In the industry data set, if a standard is set that
requires the entire batch mean distribution to conform to
acceptance criteria at expiry, which reflects the spirit of the
ICH guidance documents, then the supported shelf life
cannot be larger than about 18 months.
Fig. 9. Distribution of supported shelf lives based on six batches corresponding to a model 1: separate intercepts and separate slopes, b model
2: common intercept and separate slopes, c model 3: separate intercepts and common slope, d model 4: common intercept and common slope
(to better exhibit the relationship among the bars, the inset displays the same data but on a frequency scale of 0 to 150).
Fig. 10. Batch mean distribution and the shelf life distribution with
vertical red dashed line representing a supported shelf life that
effectively manages patient risk while satisfying business needs
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Table II is a summary using a random sample of
combination sets of six batches. Comparing Table II with
Table I, the increase from three to six batches decreased
the overall average percent of nonconforming batches from
10.6% to 6.5% and increased the proportion of batch mean
distributions completely conforming to the acceptance
criteria from 12.0% to 23.3%. These results are expected
due to the decrease in the supported shelf life when
increasing the number of batches from three to six,
reported in Fig. 8a–d and Fig. 9a–d, respectively. The
maximum supported shelf lives reported in the last column
of Table II are also similar to those reported in Table I. As
for the case of three batches, to satisfy a standard that
requires the entire batch mean distribution to conform to
acceptance criteria at expiry, the supported shelf life
cannot be larger than about 18 months.
Assessing the ICH Approach Using the Shelf Life Distribution
The earlier discussion described how the current ICH
methods manage the batch mean distribution in quantifying
patient risk. But beyond just characterizing the distribution
of batch means at the supported shelf life, it is also
important to consider the distribution of supported shelf
lives when evaluating any method that estimates the
product shelf life. Tables III and IV summarize the
supported shelf life distribution using all possible three
batch combinations (Table III) or a random sample of all
possible six batch combinations (Table IV) from the
industry data set. For example, for the 466 combinations
that fell under model 1 in Table III, the corresponding
mean supported shelf life is 22.9 months with a range of
14.3 to 39.5 months. Each of these 466 supported shelf
lives corresponds to a particular quantile of the overall
distribution of supported shelf lives that was depicted in
Fig. 3. The average of these 466 quantiles is 37.8% with a
range of 0.8% to 98.7%. Out of the 2600 supported shelf
lives derived from all possible selections of three batches
from the industry data example, 37.8% of them were less
than or equal to 22.9 months, 0.8% of them were less than
or equal to 14.3 months and 98.7% of them were less than
or equal to 39.5 months. Similar interpretations can be
made for the other models.
From Table III, it is apparent that there is a dependence
of the results of the poolability tests for selecting the best
fitted regression model on not only the mean of the supported
shelf lives (models 1 and 2 versus models 3 and 4), but also on
the corresponding quantiles of the overall supported shelf life
distribution. In addition, this dependence is more specific
when comparing quantiles for separate versus common
intercept estimates for common slope models, 58.5% versus
72.8%, respectively.
Table IV is a summary of the results for a sampling of
20,000 combinations of six batches from the 230,230 possible
combinations using the industry data set and following ICH
methods for estimating shelf life. The results are similar and
consistent with those results summarized in Table III for sets
of three batches.
For either three or six batches, if a regression model
with separate slopes among batches is selected, the
supported shelf life tends to be in the lower tail of the
overall supported shelf life distribution with mean sup-
ported shelf lives that are less than the overall mean.
Although such models do a better job of satisfying the
intent of the ICH guidance, when the estimated true
product shelf life is too short, there is an increased risk
that safe and efficacious batches will have to be discarded
at expiry. If a common slope model is selected, the
supported shelf life tends to be in the upper tail of the
overall supported shelf life distribution with mean sup-
ported shelf lives that are greater than the overall mean.
However, these estimates correspond more to situations
where a relatively high proportion of the distribution of
batch means is not in conformance at expiry, potentially
putting patients at risk.
Assessing the ICH Approach: Final Thoughts
No realistic shelf life can assure that the critical
attributes of the drug product can meet the ICH criterion
with certainty. Thus, when evaluating the performance of
any estimation procedure, the proportion of nonconforming
drug product batches at expiry must be considered in order
Table I. Summary of Proportion of Nonconforming Batches and Proportion of Combination Sets Corresponding to the Batch Mean
Distribution Being Completely Within the Acceptance Limits at Expiry for ICH-Supported Shelf Lives Determined Using Three Batch
Combinations from the Industry Data Set
Regression
model
Number of
combinations
Nonconforming batches based on the
predicted mean batch response at expiry
Combinations sets corresponding to the batch mean
distribution being completely conforming to acceptance
criteria
Average
percent
Percent
range
Number of
combinations
Mean supported
shelf life
Range of supported
shelf lives
Model 1 466 6.1% 0.0–50.0% 157 (34%) 15.6 14.3–16.5
Model 2 788 7.0% 0.0–57.7% 134 (17%) 15.1 13.3–18.1
Model 3 983 11.9% 0.0–61.5% 22 (2%) 14.9 0.0–17.6
Model 4 363 20.6% 3.8–76.9% 0 (0%) – –
Overall 2600 10.6% 0.0–76.9% 313 (12%) 15.4 0.0–18.1
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to manage the risk/benefit ratio of estimating a product shelf
life. The manufacturer and regulatory agency must come to
an agreement on allowing an a priori-defined small propor-
tion of nonconforming batches at expiry providing balance
between patient and industry risk. The conclusion reached
by considering Tables I, II, III, and IV is that the supported
shelf lives, as determined from the ICH approach, vary
greatly in both storage time and in the corresponding
quantile of the supported shelf life distribution and, as a
result, vary greatly in their ability to manage the business
needs of the manufacturer while also conforming to the
intent of the ICH guidance. Alternative approaches are
required.
CONCLUSIONS AND FURTHER RESEARCH
The evaluation of the ICH methods for estimating
shelf life presented in this paper is based on an industry
data set. The data set is composed of 26 batches of a
common drug product on stability for 24 months. Using the
industry data set as a reference, representing a finite
population of commercial production batches, allowed
evaluation of the ICH methods as would be applied to
the typical analysis of stability data for estimating a
product shelf life. Following ICH methods, shelf life
estimates were computed using poolability tests to select
the appropriate regression model then constructing 95%
confidence intervals about the overall batch mean response
or the worst case individual batch mean response depend-
ing on the regression model selected. It was shown for the
industry data set that there is approximately equal chance
of selecting one of the common slope models as compared
to one of the separate slope models for both sampling
three and six batches. The result is that the supported shelf
life for those models with separate slopes among batches is
substantially less than the supported shelf life obtained
from common slope models. Similarly, the supported shelf
life based on models with separate intercepts among
batches is less than those estimates from models with a
common intercept, although the difference is less dramatic.
A regression model that assumes both a common intercept
and slope among batches results in the longest estimates of
the supported shelf life. However, the common intercept/
slope regression model is the model selected least often
through the poolability tests.
Several issues were highlighted throughout this evalu-
ation. The batch mean distribution at expiry and the shelf
life distribution were defined and utilized to evaluate the
ICH strategy in terms of managing risk. A relationship
between the two distributions was described through the
quantiles of each. ICH puts emphasis on the batch mean
distribution to define an appropriate shelf life estimate
since according to the guidance, the objective of a stability
study is to give assurance that future batches will be safe
and efficacious at expiry. However, consideration of both
the batch mean distribution and shelf life distribution is
Table II. Summary of Proportion of Nonconforming Batches and Proportion of Combination Sets Corresponding to the Batch Mean
Distribution Being Completely Within Specification at Expiry for ICH-Supported Shelf Life Determined Using Six Batch Combinations from
the Industry Data Set
Regression
model
Number of
combinations
Nonconforming batches based on the mean batch
response at expiry
Combinations sets corresponding to the batch mean
distribution being completely conforming to
acceptance criteria
Average
percent
Percent range Number of
combinations
Mean supported
shelf life
Range of supported
shelf lives
Model 1 5035 2.7% 0.0–23.1% 2474 (49%) 15.5 14.4–16.6
Model 2 6015 3.4% 0.0–26.9% 1752 (29%) 14.8 13.8–18.1
Model 3 8451 10.0% 0.0–61.5% 131 (2%) 17.5 16.8–18.1
Model 4 499 23.7% 3.8–61.5% 0 (0%) – –
Overall 20,000 6.5% 0.0–61.5% 4357 (23%) 15.3 13.8–18.1
Table III. Summary of the Shelf Life Distribution for ICH-Supported Shelf Lives Using Three Batch Combinations from the Industry Data Set
Regression model Number of
combinations
Mean supported shelf
life (months)
Range of supported
shelf life (months)
Average of the corresponding
quantiles of the overall supported
shelf life distribution
Quantile range
Model 1 466 22.9 14.3–39.5 37.8% 0.8–98.7%
Model 2 788 23.3 13.3–40.4 37.1% 0.1–99.2%
Model 3 983 27.8 0.0–43.2 58.5% 0.1–99.7%
Model 4 363 31.2 20.9–48.0 72.8% 18.7–100.0%
Overall 2600 26.0 0.0–48.0 50.3% 0.1–100.0%
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needed to properly manage risk. Results for sampling both
three and six batches from the industry data set ranged
from a nominal to a high percentage of the batch mean
distribution being out of specification at expiry. In addition,
results from the industry data set showed a high percent-
age of the batch mean distribution being completely
conformable to acceptance criteria at expiry. Neither result
is optimal from either the patient or manufacturer per-
spective. That is, utilizing a standard that requires the
entire batch mean distribution to conform to acceptance
criteria at expiry, which is the intent of the ICH guidance,
may require the manufacturer to set the product shelf life
to a storage time that is less than estimated by their data
and, potentially, so short that the product does not satisfy
business needs.
The current ICH methods are based on considering
batches as a fixed effect in the statistical regression analyses,
similar to considering batches as a fixed factor in a typical
analysis of variance. The ramification of a fixed batch effect
analysis is that inference is restricted to only those batches
included in the stability study because only a single variance
estimate is obtained to describe both the variation among the
observed response data within batches and the variation
between batches. An alternative to the fixed batch analysis is
the so-called random batch analysis that has been discussed
for a number of years within the statistical community and
among those in other drug development areas interested in
stability issues. The random batch analysis offers two major
advantages over the fixed batch analysis. First, by incorpo-
rating batch-to-batch variability in the model, it allows for a
broader inference to all future batches, which is more in line
with the stated objectives of the ICH guidance. Second, the
random batch analysis does not require poolability testing.
Batch-to-batch differences in the intercepts and/or slopes
contribute to the overall variability in the model. The random
batch analysis strategy was applied to the industry data and
demonstrated advantages over the ICH-fixed batch analysis
results but also did not effectively manage risk. This leaves
open further discussion and research on how to estimate a
product shelf life that does not fall in the extreme left tail of
the shelf life distribution but is also not so long that an
unacceptable percentage of the product and/or batch mean
distribution exceeds acceptance limits at expiry. Research
continues on addressing these remaining issues. Current
efforts center on how to best incorporate methods based on
tolerance intervals and/or calibration techniques. Work is also
progressing on applying Bayesian methods to estimate
product shelf life and manage risk. Results of this continuing
research will be reported in a future paper.
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